Safety Study of Ch-mAb7F9 for Methamphetamine Abuse

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Methamphetamine Abuse
Interventions
BIOLOGICAL

normal saline

saline 225 ml

BIOLOGICAL

ch-mAb7f9

The single doses to be administered in each cohort are 0.2, 0.6, 2, 6, and 20 mg/kg, respectively. Volume to be administered 225 ml

Trial Locations (1)

66211

Quintiles Phase 1 Services, Overland Park

Sponsors
All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

University of Arkansas

OTHER

lead

InterveXion Therapeutics, LLC

INDUSTRY